Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase-Reference-Cited by-同舟云学术

Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase

Published:2011 Issue:2 Volume:48 Page:149-153
ISSN:1880-5086
Container-title:Journal of Clinical Biochemistry and Nutrition
language:en
Short-container-title:J. Clin. Biochem. Nutr.

Author:

Tanigawa Tetsuya,Watanabe Toshio,Ohkawa Fumikazu,Nadatani Yuji,Otani Koji,Machida Hirohisa,Okazaki Hirotoshi,Yamagami Hirokazu,Watanabe Kenji,Tominaga Kazunari,Fujiwara Yasuhiro,Takeuchi Koji,Arakawa Tetsuo

Publisher

The Society for Free Radical Research Japan

Subject

Clinical Biochemistry,Nutrition and Dietetics,Medicine (miscellaneous)

Reference32 articles.

1. Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?

2. 15-Hydroxyprostaglandin dehydrogenase

3. 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications

4. 4 Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci, 1998; 43 Suppl: 5S-13S.

5. Rebamipide Reduces Delay in Gastric Ulcer Healing in Cyclooxygenase-2-Deficient Mice

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians;Terapevticheskii arkhiv;2022-10-12

2. Rebamipide: evidence base for use in gastroenterology;Terapevticheskii arkhiv;2020-12-15

3. The Lactobacillus brevis 47 f Strain Protects the Murine Intestine from Enteropathy Induced by 5-Fluorouracil;Microorganisms;2020-06-09

4. New Prospects of Cytoprotection in the Treatment and Prevention of Gastric and Intestinal Diseases (Resolution of an Expert Council and Literature Review);Russian Journal of Gastroenterology, Hepatology, Coloproctology;2020-05-06

5. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study;PLOS ONE;2019-05-08